

Nucleofection® Protocol for MDA-MB-468 cells – Transfection in Suspension

Transfection Efficiency and Viability

This Optimized Protocol describes how to transfect MDA-MB-468 cells on the 4D-Nucleofector® System or the HT Nucleofector® Instrument. Transfection efficiencies of up to 80% can be achieved using Pulse Code DS-120 and 0.4 µg of pmaxGFP™ Vector in 20 µL Nucleovette® Strips (analyzed 24h post-Nucleofection® by flow cytometry). The cell viability of 63-81% was determined using the ViaLight® Plus Assay and normalized to untransfected control samples. Similar transfection efficiencies can be achieved with 100 µL, 20 µL, single-well, 16-well, 96-well, and 384-well Nucleofection® Vessels as it is possible to transfer the experimental settings between systems. Visit the **Lonza Knowledge Center** for more information, including citations.

	0			
Kit contents				
Cat. No	V4XC-1012/ V4XC-1024	V4XC-1032	V4SC-1096/ V4SC-1960	V5SC-1002*/ V5SC-1010*
Transfection volume	100 μL	20 μL	20 μL	20 μL
Size [reaction]	12/ 24	2 x 16	1 x 96/ 10 x 96	2 x 384/ 10 x 384
SE Cell Line Nucleofector® Solution	2 x 0.675 mL/ 2.25 mL	0.675 mL	2.25 mL/ 22.5 mL	22.5 mL/ 90 mL
Supplement 1	2 x 0.15 mL/ 0.5 mL	0.15 mL	0.5 mL/ 5 mL	5 mL/ 20 mL
pmaxGFP [™] Vector (1 μg/μL in 10 mM Tris pH 8.0)	50 μg	50 μg	50 µg	50 µg/ 150 µg
Single Nucleocuvette® Vessel (100 µL)	12/24	-	-	-
16-well Nucleocuvette® Strips (20 µL)	-	2	-	-
96-well Nucleocuvette® Plate (20 µL)	-	-	1/10	-
384-well Nucleocuvette® Plate (20 µL)*	-	-	-	2/10
To be used in conjunction with	4D-Nucleofector [®] Core and X Unit	4D-Nucleofector® Core and X Unit	4D-Nucleofector [®] Core and 96-well Unit	384-well Nucleofector® System

^{* 384-}well Nucleocuvette® plates are best handled with a liquid handling system. Contact **Scientific Support** for automation support.

Recommended kits: SE Cell Line Nucleofector® Kits

The SE Cell Line Kits are used with the 4D-Nucleofector® System or the high-throughput 384-well Nucleofector® Instrument for efficient transfection of various mammalian cells including


MDA-MB-468 cells. The kits consist of two components that are not sold individually (conductive polymer cuvettes and a solution box) and are available in a single, 16-well, 96-well, and 384-well Nucleocuvette® Format. SE Cell Line Kit components are listed in the table above.



Storage and Stability

Nucleofector® SE Cell Line Kits are shipped at room temperature. After receiving the kits, store Nucleofector® Solution, Supplement, and pmaxGFP™ Vector at 2–8°C and Nucleocuvette® Vessels at room temperature. For long-term storage, pmaxGFP™ Vector is ideally stored at -20°C. The expiration date is printed on the solution box. Once the Nucleofector® Supplement is added to the Nucleofector® Solution, it is stable for three months at 4°C.

4D-Nucleofector® X Unit process



Required Material

- Respective Nucleofector® System
- Supplemented SE Cell Line Nucleofector[®] Solution at room temperature

Note

Please make sure to add Supplement 1 to the Nucleofector® Solution. The ratio of Nucleofector® Solution to Supplement is 4.5:1 (see Table 1). Prepare enough supplemented solution for the number of samples you want to transfect (see Table 3).

- Respective Nucleocuvette[®] Vessel
- If working with 20 µL Nucleocuvette® Strips or Plates: Suitable pipette tips. Please make sure that your pipette tips reach the bottom of the Nucleocuvette® Wells without getting stuck
- If working with 384-well or 96-well Nucleocuvette®
 Plates: The 384-well Nucleofector® System and the
 4D Nucleofector® 96-Well Unit can be used either
 manually or automated on standard liquid handling
 instruments. For automated processing,
 consumables specific to your respective liquid
 handling system are required. For manual
 processing, we recommend using a multi-channel
 pipette
- Substrate of interest, highly purified, preferably by using endotoxin-free kits; for plasmid DNA A260/A280 ratio should be ~1.8
- Supplied pmaxGFP™ Vector, stock solution 1 µg/µL

Note

When using pmaxGFP™ as a positive control, dilute the stock solution to an appropriate working



concentration. Further details are provided in Table 3.

The volume of substrate solution added to each sample should not exceed 10% of the total reaction volume (2 μ L for 20 μ L reactions; 10 μ L for 100 μ L reactions).

- · Cell culture plates of your choice
- For trypsinization: 0.5 mg/mL Trypsin and 0.2 mg/mL EDTA in PBS (5x concentrated) and supplemented culture media or PBS/0.5% BSA
- Culture medium: Leibovitz L-15 supplemented with 10 % calf serum (FCS), 100µg/mL streptomycin, 100U/mL Penicillin, 2mM glutamine. Prewarm appropriate volume of culture medium to 37°C (see Table 2)
- Recovery medium (optional): Low calcium medium, e.g. RPMI
- Appropriate number of cells/sample (see Table 2)

Pre Nucleofection®

Cell Culture Recommendations

The viability and overall health of cells prior to transfection is well known to be important for optimal transfection results. Prior to transfection, cells should be at least 90% viable and have had adequate time to recover from passaging. We recommend the following culture conditions for MDA-MB-468:

- Culture cells without CO₂
- Replace media every 2–3 days (3 times per week)
- Passage cells at 85
- Passage cells at 85-95% confluency
- Seed out 2,0 x10⁴ cells/cm²
- Subculture cells 2 days before a Nucleofection[®] Experiment
- Optimal confluency for Nucleofection[®]
 Experiments: 80–90%. Higher cell densities may cause lower Nucleofection[®] Efficiencies

Trypsinization

- Remove media from the cultured cells and wash cells once with PBS; use at least same volume of PBS as culture medium
- For harvesting the cells, incubate the cells at 37°C with 0.5mg/mL trypsin/0.2mg/mL EDTA
- Inactivate trypsinization reaction with supplemented culture medium or PBS/0.5% BSA

Nucleofection®

Table 3 shows the recommended amount of substrate, cell number, and Nucleofection® Pulse Code for each sample.

- Please make sure that Supplement 1 has been added to the required amount of Nucleofector® SE Cell Line Solution (see Table 1)
- Start your respective Nucleofector® System and create or upload the experimental parameter file (see device manual for details)
- Select/Check for the appropriate Nucleofector[®]
 Pulse Code (see Table 3, we recommend pulse code DS-120 for the X Unit or corresponding programs for other units / instruments)
- Prepare cell culture plates by filling an appropriate number of wells with the recommended volume of culture media (see Table 4) and preincubate/equilibrate the plates in a humidified 37°C/5% CO₂ incubator
- Prewarm an aliquot of culture medium to 37°C (see Table 4)
- Make sure to dilute your substrate to the recommended working concentration (see Table 3).
- Harvest the cells by trypsinization (see Trypsinization)
- Take an aliquot of the cell suspension and count cells to determine the cell density
- Transfer the required amount of cells (see Table 3) to a new tube and pellet by centrifugation at 90xg for 10 minutes at room temperature. Gently remove all supernatant. Note that cell pellet may be looser than normal.
- Resuspend the cell pellet carefully at room temperature in supplemented Nucleofector[®] SE Cell Line Solution (see Table 3). Gently pipette the cells to obtain a single-cell suspension.
- Prepare master mixes by dividing cell suspension according to the number of substrates
- Add required amount of substrates to each aliquot (max. 10% of final sample volume)



Note

When working with RNA, it is recommended to avoid longer incubation times as RNA is susceptible to degradation, although Nucleofector® Solutions are tested for absence of RNase activity

 Transfer master mixes into the respective Nucleocuvette® Vessels

Note

It is important to work as quickly as possible as leaving cells in Nucleofector® Solution for extended periods of time may lead to reduced transfection efficiency and viability. Avoid air bubbles while pipetting. When working in a 96- or 384-well format it is recommended to either pre-dispense each cell suspension into a sterile round-bottom 96-well plate or to use reservoirs for multichannel pipettes.

 Gently tap the Nucleocuvette® Vessels on the benchtop to make sure the sample covers the bottom of the reaction vessel

Note

When using the 384-well Nucleocuvette® Plate, instead of tapping you may briefly shake it with an appropriate microtiter-plate shaker to make sure the sample covers the bottom and sides of the wells without air bubbles.

- Place Nucleocuvette® Vessel with closed lid into the retainer of the Nucleofector® System. Check for proper orientation of the Nucleocuvette® Vessel
- Start the Nucleofection® Process by pressing "Start" on the display of your Nucleofector® System (for details, please refer to the respective device manual)
- After the Nucleofection® Process is completed, carefully remove the Nucleocuvette® Vessel from the retainer
- Optional: A recovery step can help to improve viability after the Nucleofection® Experiment. Add 100–300 µL pre-equilibrated recovery medium to the cuvette (instead of the standard culture media) and gently transfer it to a reaction tube. Place the cell suspension in an incubator for 5–10 minutes. Transfer the sample into the prepared culture dish and continue with Post-Nucleofection®
- Resuspend cells with prewarmed medium (for recommended volumes see Table 4). Mix cells by gently pipetting up and down two to three times.

- When working with the 100 µL Nucleocuvette® Vessels, use the supplied pipettes and avoid repeated aspiration of the sample
- Plate desired amount of cells in culture system of your choice (for recommended volumes, see Table 4)

Post Nucleofection®

Incubate the cells in humidified 37°C/5% CO₂ incubator until analysis. Gene expression or downregulation, respectively, is often detected after just 4–8 hours.

Selected References

- Marquis, Carolyn et al. "Chromosomally unstable tumor cells specifically require KIF18A for proliferation." Nature communications vol. 12,1 1213. 22 Feb. 2021, doi:10.1038/s41467-021-21447-2
- Guo, Qiuchen et al. "Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro." Blood advances vol. 6,20 (2022): 5668-5675. doi:10.1182 /bloodadvances.2021006120
- Azimi, Iman et al. "TRPC1 is a differential regulator of hypoxia-mediated events and Akt signalling in PTEN-deficient breast cancer cells." Journal of cell science vol. 130,14 (2017): 2292-2305. doi:10.1242/jcs.196659

Lonza

Table 1: Volumes required for a single reaction

	100 μL	20 μL	
Volume of Nucleofector® Solution	82 µL	16.4 µL	
Volume of Supplement	18 μL	3.6 µL	

Table 2: Required amounts of cells and media for a Nucleofection® Reaction

		16-well/ 96-well	384-well
Reaction volume	100 μL	20 μL	20 μL
Culture medium per sample post- Nucleofection® (for transfer and culture)	1.4 mL	255 μL	255 μL
Cell number per Nucleofection® Sample	1 x 10 ⁶ (Lower or higher cell numbers may influence transfection results)		2 x 10 ⁵ (Lower or higher cell numbers may influence transfection results)

Table 3: Contents of one Nucleofection® Sample and recommended Pulse Code

		Single Nucleocuvette [®] Vessel	16-well Nucleocuvette [®] Strips	96-well Nucleocuvette [®] Plate	384-well Nucleocuvette [®] Plate
Reaction volume		100 µL	20 μL	20 μL	20 μL
Cells		1 x 10 ⁶	1 x 10 ⁵	1 x 10 ⁵	1 x 10 ⁵
Substrate*	pmaxGFP™ Vector	2 μg	0.4 μg	0.4 μg	0.4 μg
or	plasmid DNA (in H ₂ O or TE)	2-10 μg	0.4-2 μg	0.4-2 μg	0.4-2 μg
or	siRNA	30–300nM siRNA (3–30 pmol/sample)	30–300nM siRNA (0.6–6 pmol/sample)	30–300nM siRNA (0.6–6 pmol/sample)	30–300nM siRNA (0.6–6 pmol/sample)
or	mRNA	effects, while too little	e RNA can lead to poor	each new mRNA. Too mu r expression. RNA charac) can have a significant in	teristics such as size or
or	RNPs		eriment should be perfo lar ratio has been estal	ormed to find the ideal RN blished	P concentration after an
SE Cell Line	Solution	100 μL	20 μL	20 μL	20 μL
Pulse Code		DS-120	DS-120	96-DS-120	DS-120-AA

^{*} Volume of the substrate should comprise a maximum of 10% of the total reaction volume

Table 4: Culture volumes required for post Nucleofection® Steps and sample transfer

	16-well / 96-well*	384-well**
100 μL	20 μL	20 μL
1 mL	-	-
-	180 µL	185 µL
400 μL	80 µL	40 μL
complete sample (use supplied pipettes)	20 μL	15 µL
	1 mL - 400 μL complete sample (use	100 μL 20 μL 1 mL 180 μL 400 μL 80 μL complete sample (use 20 μL

^{*} Maximum cuvette volume 200 µL ** Maximum well volumne 60 µL



Additional Information

For additional information and an up-to-date list of Nucleofector® References, please visit the Lonza Knowledge Center:

https://knowledge.lonza.com

For more technical assistance, contact our Scientific Support Team:

USA /Canada

Phone: 800 521 0390 (toll-free)

Fax: 301 845 8338

Email: scientific.support@lonza.com

Europe and Rest of World

Phone: +49 221 99199 400 Fax: +49 221 99199 499

Email: scientific.support.eu@lonza.com

Lonza Cologne GmbH - 50829 Cologne Germany

For research use only. Not for use in diagnostic procedures. The Nucleofector® Technology is covered by patent and/or patent pending rights owned by the Lonza Group Ltd or its affiliates. The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well Shuttle® System and Nucleocuvette® Plates and Modules is covered by patent and/or patent pending rights owned by Lonza Cologne GmbH. Nucleofector, Nucleofection, Nucleocuvette, maxGFP and 96-well Shuttle are trademarks of Lonza Cologne GmbH in Germany and / or the U.S. and / or other countries

All trademarks belong to Lonza, registered in USA, EU or CH or to third party owners and used only for informational purposes. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights. The user bears the sole responsibility for determining the existence of any such third party rights, as well as obtaining any necessary licenses. For more details: www.lonza.com/legal.

©2022 Lonza. All rights reserved. OP-CL031-MDA-MB-468_1122